Wall Street Analysts Think Monte Rosa Therapeutics Could Surge 100.47 percent Read This Before Placing a Bet
| GLUE Stock | USD 9.11 0.51 5.93% |
About 54% of Monte Rosa's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Monte Rosa Therapeutics suggests that some traders are interested. The current market sentiment, together with Monte Rosa's historical and current headlines, can help investors time the market. In addition, many technical investors use Monte Rosa Therapeutics stock news signals to limit their universe of possible portfolio assets.
Monte |
The mean of analysts price targets for Monte Rosa Therapeutics points to a 100.5 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at zacks.com
 |
Monte Rosa Fundamental Analysis
We analyze Monte Rosa's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monte Rosa using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monte Rosa based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Monte Rosa is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Monte Rosa Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monte Rosa stock to make a market-neutral strategy. Peer analysis of Monte Rosa could also be used in its relative valuation, which is a method of valuing Monte Rosa by comparing valuation metrics with similar companies.
Peers
Monte Rosa Related Equities
| NKTX | Nkarta | 14.56 | ||||
| ERAS | Erasca | 5.04 | ||||
| SANA | Sana Biotechnology | 4.08 | ||||
| FHTX | Foghorn Therapeutics | 3.59 | ||||
| KYMR | Kymera Therapeutics | 1.91 | ||||
| STOK | Stoke Therapeutics | 1.19 | ||||
| LYEL | Lyell Immunopharma | 1.10 | ||||
| STTK | Shattuck Labs | 0.93 | ||||
| HOWL | Werewolf Therapeutics | 0.51 | ||||
| GBIO | Generation Bio | 0.69 | ||||
| IKNA | Ikena Oncology | 1.17 | ||||
| NRIX | Nurix Therapeutics | 2.57 | ||||
| DSGN | Design Therapeutics | 2.93 |
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |